All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Bookmark this article
Quadruplet induction therapy consisting of daratumumab, carfilzomib, lenalidomide, and dexamethasone has shown durable depth and duration of responses in patients with newly diagnosed multiple myeloma, including those treated with autologous stem cell transplantation (ASCT).1 However, the clinical benefit of continuous quadruplet therapy after transplant and its associated patient response has yet to be fully explored.1
In order to bridge this knowledge gap, Costa1 carried out the MASTER trial (NCT03224507), which aimed to determine the rate of measurable residual disease (MRD) negative responses with quadruplet induction therapy and a response-adapted consolidation. We summarize the final analysis presented at the European Hematology Association 2023 Hybrid Congress. For prior results and more information on the MASTER trial, check out our previous article here.
Figure 1. Rates of overall MRD and sustained MRD after 12 months according to the number of high-risk cytogenetic abnormalities*
MRD, measurable residual disease.
*Adapted from Costa.1
Figure 2. Rates of 3-year OS and 3-year PFS according to the number of high-risk cytogenetic abnormalities*
OS, overall survival; PFS, progression-free survival.
*Adapted from Costa.1
Figure 3. Rates of 3-year OS and 3-year PFS according to the number of high-risk cytogenetic abnormalities in patients who achieved an MRD-negative treatment-free state*
MRD, measurable residual disease; OS, overall survival; PFS, progression-free survival.
*Adapted from Costa.1
In patients reaching MRD-SURE status (N = 84):
The adverse events reported in this final analysis did not differ much from previous reports, with 74% of patients experiencing an adverse event of Grade 3 or greater (for further details, see here). Additionally:
The final results from the MASTER trial show durable clinical responses for quadruplet induction therapy, with most patients who achieved treatment cessation having standard or high-risk cytogenetics. Moreover, around 80% of patients with either zero or one high-risk cytogenetic abnormality achieved MRD negativity. In contrast, achieving a sustained MRD-negative status in patients with ultra-high-risk cytogenetics remains an important unmet need. Future directions should now include new agents and mechanisms of action directed towards patients with persistent MRD as well as exploring the possibility of deferring ASCT in early MRD-negative patients.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox